 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
United Therapeutics Corporation (UTHR) is a biotechnology company.
The firm focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH).
The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trials for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer.
Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases.
Shares have formed a bullish "flag" and higher share prices are expected for this stock. The rally in shares came after the U.S. Food and Drug Administration (FDA) approved the oral use of Remodulin (treprostinil) for the treatment of pulmonary arterial hypertension.
52-Week Trading Range: $52.38 - $116.6
Entry Point: $114.00
Stop Loss: $108.30
Target Price: $125.40
UTHR fell below our stop loss.
